title: Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
abstract: HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14). At week 96, 27% of patients on alendronate versus 96% of controls presented with osteoporosis. Spine bone mineral density (BMD) increases were detected at week 48, and progressed thereafter. Improvements in trochanter BMD were obtained after 2 years. Once-weekly oral alendronate may be an effective and safe treatment for HIV-1-associated osteoporosis.
authors.affiliation: Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Spain.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Negredo
authors.forename: Eva
authors.initials: E
authors.lastname: Martínez-López
authors.forename: Roger
authors.initials: R
authors.lastname: Paredes
authors.forename: Joaquim
authors.initials: J
authors.lastname: Rosales
authors.forename: Núria
authors.initials: N
authors.lastname: Pérez-Alvarez
authors.forename: Susana
authors.initials: S
authors.lastname: Holgado
authors.forename: Silvia
authors.initials: S
authors.lastname: Gel
authors.forename: Luís
authors.initials: L
authors.lastname: del Rio
authors.forename: Xavier
authors.initials: X
authors.lastname: Tena
authors.forename: Celestino
authors.initials: C
authors.lastname: Rey-Joly
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
mesh_terms: D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006801:Humans; D010024:Osteoporosis / Q000178:diet therapy / Q000188:drug therapy* / Q000821:virology; D010865:Pilot Projects
chemical_list: D019386:Alendronate